We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Well done chester, I was delighted to just catch the close today and see us back at 15/15.25, tremendous holding, best of luck.
Crumbs and Inanaco
Thank you it was all my own work............. lol
Chester.
Ray its taken a while to get there and it would not have happened without the unhelpful delays to the trials and the Capital Finance fiasco ( thanks to Woodford ) and a few non-believers.... hallelujah .... scaring off potential buyers.
And the depth of posting on here that got me hooked on the details and the prize of a truly game changing way to fight cancer.
I'll stop there, its getting like an award acceptance speech........ : )
Chester.
good for you chap ... all about the number you hold ..
Well done Chester. You might find the remaining 99.75% a little harder to accumulated :-)
so the more the virus infects ........ the higher risk of mutation ... its not a "Time thing" its the number infected thing that is what increases the risk of mutation .. so 100,000,000 infected could result in rapid mutation ... but 1000 infected would not see that mutation just not enough on going replication
Well done Chester
I think the delivery would be the clincher for a deal...
We know all pharma want to do what they can in this Covid crisis... mostly that involves them going through all their catalogue of drugs looking for anything that may do something... Others have their own vaccines and then there is the partnering route well scancell have a product with form and backing science that is growing and now it has Gov funding too...
Just hit a milestone in my own journey to own Scancell ....... : )
After todays trades now own 0.25% of the company, took a long time but had to share my joy..
Chester.
Back in the spring, at the Los Alamos National Laboratory in New Mexico, the computational biologist Bette Korber and her team were busy building the mathematical tools that would flag up such repeat offenders in the GISAID data.
“We didn’t expect to see anything so quickly,” she says. But already they had a candidate: “The D614G mutation stood out as such a case by early April.”
D614G refers to a switch in amino acid – from aspartate (D) to glycine (G) – at position 614 in the sequence of the protein that makes up the spikes of Sars-CoV-2. The spike is the protruding structure on the surface of the virus that binds to a human cell, allowing the virus to break in . After it has replicated inside the cell, its offspring break out again – killing the cell – and go on to infect others.
When Sars-CoV-2 emerged in Wuhan, it had a D at position 614. By June, G had replaced D almost everywhere in the world.
https://www.theguardian.com/world/2020/sep/18/mutant-virus-should-we-be-worried-sars-cov-2-changing-covid
Exactly and IB can target multiple epitopes on the same protein.
What I am keen to know more about is the delivery method. This is research that Lindy instigated some time ago well prior to the Covid19 crisis.
every day that covid spreads .... its multiplying ............ every day is the chance of a mutation of the spike that renders all these spike vaccines redundant .... they have to Start again from Scratch .... Scancell at this moment in time its a tweak ... but it also targets the core of the virus which does not change . .....
But I do think Cliff could be very busy from now onwards
Strings not string....What we know is it is very likely a deal on one MaB is likely to be concluded in the coming days / weeks...
But with as many strings as scancell have the potential is for many deals on all platforms with many products and multiple potential targets.... I agree with nana a major pharma could make a move in on Covidity at any moment... I'm sure there is interest there.
I think Cliff is a time traveller.
Moving clocks run slow.
the pre-clinical Covid data ........... could just as easily attract a major pharma .. especially as Scancells vaccine has quality human data in its history
Oxfords vaccine after all attract AZN despite the same format failing in Flu and prostate cancer
So it's the proverbial piece of string .
1. Closer than yesterday
2. When a deal is closed
1.) How close are we?
2.) When can expect news of any such deal/ deals.?